Literature DB >> 30075127

Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy.

Elizabeth L Siegler1, Yanni Zhu2, Pin Wang3, Lili Yang4.   

Abstract

CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome. In this issue of Cell Stem Cell, Li et al. (2018) describe how engineered iPSC-derived NK cells armed with NK-tailored CAR constructs (CAR-iPSC-NK cells) provide better options for anti-cancer immunotherapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30075127     DOI： 10.1016/j.stem.2018.07.007

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN： 1875-9777            Impact factor:   24.633


  39 in total

Review 1.  Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell-based therapeutics?

Authors:  Daniel R Ram; Cordelia Manickam; Olivier Lucar; Spandan V Shah; R Keith Reeves
Journal:  J Leukoc Biol       Date:  2019-02-07       Impact factor: 4.962

Review 2.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 3.  The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells.

Authors:  Jake Moscarelli; David Zahavi; Rachael Maynard; Louis M Weiner
Journal:  Transplant Cell Ther       Date:  2022-07-03

Review 4.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 5.  Advances in NK cell production.

Authors:  Fang Fang; Siqi Xie; Minhua Chen; Yutong Li; Jingjing Yue; Jie Ma; Xun Shu; Yongge He; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-05       Impact factor: 22.096

Review 6.  Paving the way towards universal treatment with allogenic T cells.

Authors:  Michelle H Townsend; Kelsey Bennion; Richard A Robison; Kim L O'Neill
Journal:  Immunol Res       Date:  2020-02       Impact factor: 2.829

7.  Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.

Authors:  Senlian Hong; Chenhua Yu; Peng Wang; Yujie Shi; Weiqian Cao; Bo Cheng; Digantkumar G Chapla; Yuanhui Ma; Jie Li; Emily Rodrigues; Yoshiki Narimatsu; John R Yates; Xing Chen; Henrik Clausen; Kelly W Moremen; Matthew Scott Macauley; James C Paulson; Peng Wu
Journal:  Angew Chem Int Ed Engl       Date:  2020-12-14       Impact factor: 15.336

8.  Intramuscular Expression of Plasmid-Encoded FVII-Fc Immunoconjugate for Tumor Immunotherapy by Targeting Tumoral Blood Vessels and Cells.

Authors:  Liping Ma; Guanru Wang; Sijia Liu; Feng Bi; Ming Liu; Gang Wang
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 9.  CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.

Authors:  Faroogh Marofi; Marwan Mahmood Saleh; Heshu Sulaiman Rahman; Wanich Suksatan; Moaed E Al-Gazally; Walid Kamal Abdelbasset; Lakshmi Thangavelu; Alexei Valerievich Yumashev; Ali Hassanzadeh; Mahboubeh Yazdanifar; Roza Motavalli; Yashwant Pathak; Adel Naimi; Behzad Baradaran; Marzieh Nikoo; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-07-02       Impact factor: 6.832

Review 10.  CAR-NK Cell: A New Paradigm in Tumor Immunotherapy.

Authors:  Faroogh Marofi; Alaa S Al-Awad; Heshu Sulaiman Rahman; Alexander Markov; Walid Kamal Abdelbasset; Yulianna Ivanovna Enina; Mahnaz Mahmoodi; Ali Hassanzadeh; Mahboubeh Yazdanifar; Max Stanley Chartrand; Mostafa Jarahian
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.